L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile

• Verfasst von: Kommoss, Felix [VerfasserIn]
• Titel: L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile
• Verf.angabe: Felix KF Kommoss, Anthony N. Karnezis, Friedrich Kommoss, Aline Talhouk, Florin-Andrei Taran, Annette Staebler, C. Blake Gilks, David G. Huntsman, Bernhard Krämer, Sara Y. Brucker, Jessica N. McAlpine and Stefan Kommoss
• E-Jahr: 2018
• Jahr: 27 July 2018
• Umfang: 7 S.
• Fussnoten: Gesehen am 16.12.2019
• Titel Quelle: Enthalten in: British journal of cancer
• Ort Quelle: Edinburgh : Nature Publ. Group, 1999
• Jahr Quelle: 2018
• Band/Heft Quelle: 119(2018), 4, Seite 480-486
• ISSN Quelle: 1532-1827
• DOI: doi:10.1038/s41416-018-0187-6
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1685689396

Abstract

The newly developed Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) has consistently been shown to be prognostically significant in endometrial carcinomas (EC). Recently, we and others have demonstrated L1 cell-adhesion molecule (L1CAM) to be a significant indicator of high-risk disease in EC. In the current study, it was our aim to determine the prognostic significance of aberrant L1CAM expression in ProMisE subgroups in a large, single centre, population-based EC cohort.